In the expanded testing panel that used advances in genetic testing assays, PIK3CA, AKT1 and PTEN alterations were identified in tumours from 76 (54%) of the 140 participants in the intention-to-treat population (39 who received capivasertib and 37 who received placebo). Here, PIK3CA is linked to neoplasm.